Morgan Stanley-Backed Sterling Accuris Reports ₹231 Crore Revenue in FY26 as Losses Widen 38%

Margin Compression

Net Loss

₹32.0 Crore

₹23.2 Crore

+37.9% (Loss widened)

Total Expenses

₹259.5 Crore

₹220.8 Crore

+17.5%

Analysis of Major Expense Drivers (₹259.5 Crore Total Outgo)

The widening loss profile reflects heavy fixed overheads required to scale a decentralized laboratory network:

• High Fixed Talent Costs: Employee benefit expenses rose to ₹59.0 crore, accounting for nearly 23% of total costs.
• Specialist Doctor & Pathologist Fees: Professional fees paid to consulting pathologists, radiologists, and lab directors reached ₹42.8 crore.
• Reagent & Testing Consumables: Diagnostic materials and testing kits stood at ₹52.2 crore, driven by sticky input costs and testing volume inflation.
• Lab Setup & Logistical Capex: Depreciation on advanced testing equipment, facility rents, and cold-chain sample transport logistics accounted for the remaining cost base.

The Operating Leverage Challenge in Retail Diagnostics

The financial performance of Sterling Accuris illustrates the evolving unit economics of regional diagnostic chains in India:

• The Sample Density Requirement: Building accredited reference laboratories in Tier-2 and Tier-3 markets requires upfront capital expenditure that typically demands 24 to 36 months of high-volume sample throughput to achieve operating break-even.
• Competitive Pricing Pressure: Rapid expansion into non-metro regions faces fierce price competition from established pan-India diagnostic brands and discounted B2C healthtech aggregators, limiting pricing power.
• Fixed vs. Variable Cost Imbalance: While revenue grew 16%, high fixed overheads (specialist retainers and accreditation compliance) expanded at a faster pace, compressing operating margins.